Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226558 · ClinicalTrials.gov registry record
Long-Term Outcomes of Children With Congenital CMV in New York State
A clinical trial of Sensorineural Hearing Loss and Congenital CMV Infection, sponsored by Stony Brook University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06226558: Recruiting study of Sensorineural Hearing Loss and Congenital CMV Infection, sponsored by Stony Brook University.
NCT06226558 is a study of Sensorineural Hearing Loss and Congenital CMV Infection that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 1,000 participants, above the 54-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (1752% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06226558, a study of Sensorineural Hearing Loss and Congenital CMV Infection, is actively recruiting participants, sponsored by Stony Brook University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital CMV, from those babies with more severe findings to those with no symptoms. In particular, our study will provide new information about many facets of congenital CMV, including: * Developmental, hearing, neurologic, and vision outcomes * The spectrum and timing of symptoms * The impact congenital CMV has on the baby and its family * How many babies are infected with congenital CMV in New York State How antiviral medications and other interventions impact outcomes of children with congenital CMV Throughout the duration of the study, children will undergo routine developmental and hearing assessments, which will assist with early diagnosis of any infection complications. Any child found to have a neurodevelopmental, hearing, or vision abnormality will be referred for appropriate evaluation and treatment. Families will also be asked to complete periodic surveys about their experience with congenital CMV, both as a medical diagnosis and as it affects their day-to-day activities.
Primary Outcome
To determine the rate of confirmed congenital CMV in a statewide cohort
Conditions Studied
Study Locations (1)
New York
- Stony Brook Children's Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-10-01 |
What NCT06226558 shows while recruiting
NCT06226558 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 54-participant average among 13 other Sensorineural Hearing Loss trials with a reported enrollment target (1752% higher).
The record links to 2 conditions, with Sensorineural Hearing Loss appearing as the primary indexed condition, and to 0 interventions.
NCT06226558 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06226558 about?
NCT06226558 is a clinical study titled "Long-Term Outcomes of Children With Congenital CMV in New York State". PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congen...
What is the current status of trial NCT06226558?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-02-01. Estimated completion is 2026-10-01.
What conditions does trial NCT06226558 study?
This clinical trial studies the following conditions: Sensorineural Hearing Loss, Congenital CMV Infection.
Who is sponsoring clinical trial NCT06226558?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226558 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sensorineural Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06226558's enrollment target sits among peer trials
1,000 1st of 13 higher than 13 of 13 other Sensorineural Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sensorineural Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Perceptual Adaptation Following Cochlear Implantation (Aim 3a)
RECRUITING · NA
-
Quantification of Visually Evoked Cortical Potentials in Individuals With Hearing Loss
RECRUITING
-
Effects of Clear Speech on Listening Effort and Memory in Sentence Processing
RECRUITING · NA
-
Long-term Follow-up of a Cochlear Implant With Dexamethasone Eluting Electrode Array
RECRUITING
-
Social Influences on Sensorimotor Integration of Speech Production and Perception During Early Vocal Learning
RECRUITING · NA
-
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI